

Addendum¹ to
***"The use of stems in the selection of International
Nonproprietary Names (INN) for pharmaceutical
substances"*** WHO/EMP/RHT/TSN/2018.1

Programme on International Nonproprietary Names (INN)

***Health Products Policy and Standards (HPS)
Access to Medicines and Health Products (MHP)***

World Health Organization, Geneva

© World Health Organization 2020 - All rights reserved. The contents of this document may not be reviewed, abstracted, quoted, referenced, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means, without explicit prior authorization of the WHO INN Programme.

This document contains the collective views of the INN Expert Group and does not necessarily represent the decisions or the stated policy of the World Health Organization.

Addendum¹ to "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" - WHO/EMP/RHT/TSN/2018.1

¹ This addendum is a cumulative list of all new stems selected by the INN Expert Group since the publication of *"The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances"* 2018.

-adenant	adenosine receptors antagonists
-----------------	--

ciforadenant (118), inupadenant (123), preladenant (99), taminadenant (120), tozadenant (106), vipadenant (103)

-caftor	cystic fibrosis transmembrane regulator (CFTR) protein modulators, correctors, and amplifiers
----------------	--

bamocaftor (121), deutivacaftor (118), dirocaftor (123), elexacaftor (121), galicaftor (119), icenticaftor (122), ivacaftor (104), lumacaftor (105), navocaftor (121), nesolicaftor (122), olacaftor (119), posenacaftor (122), tezacaftor (114)

-calcet/-calcet-	calcium-sensing receptors (CaSR) agonists
-------------------------	--

cinacalcet (88), etelcalcetide (112), evocalcet (113), tecalcet (87), upacalcet (118)

-cerfont	corticotropin-releasing factor (CRF) receptor antagonists
-----------------	--

crinecerfont (120), emicerfont (102), pexacerfont (97), tildacerfont (119), verucerfont (102)

-copan	complement receptor antagonists/ complement inhibitors
---------------	---

avacopan (114), danicopan (119), iptacopan (122), nomacopan (119)

(c) category: pegcetacoplan (120), zilucoplan (118)

-corat	glucocorticoid receptor agonists
---------------	---

dagrocorat (111), fosdagrocorat (111), mapracorat (102), tomicorat (108), velsecorat (121)

-espib**heat shock protein (HSP) 90 inhibitors (other than –mycin)**

icapamespib (123), ganetespib (105), luminespib (108), onalespib (112), pimitespib (121), zelavespib (123)

-fexor**farnesoid X receptor agonists**

cilofexor (119), nidufexor (118), tropifexor (116), turofexorate isopropyl (103), vonafexor (122)

-fusp**fusion proteins¹**

bintrafusp alfa (121), cinrebafusp alfa (121), clervonafusp alfa (120), lorukafusp alfa (120), modakafusp alfa (122), onfekafusp alfa (118), oplunofusp (123), pabinafusp alfa (120), rozibafusp alfa (120), simlukafusp alfa (121), tagraxofusp (118), tebentafusp (118), valanafusp alfa (118)

-golix**gonadotropin releasing hormone (GnRH) antagonists**

elagolix (99), linzagolix (118), opigolix (118), relugolix (107), sufugolix (89)

-irine**cytotoxic pyrrolbenzodiazepine dimers and analogues**

camidanlumab tesirine (117), loncastuximab tesirine (117), mipasetamab uzoptirine (123), rolinsatamab talirine (119), rovalpituzumab tesirine (114), serclutamab talirine (120), tamrintamab pamozirine (120), vadastuximab talirine (113)

-ixafor**chemokine CXCR4 antagonists**

balixafortide (112), burixafor (104), mavorixafor (118), motixafortide (120), plerixafor (93)

¹ A fusion protein is defined as a multifunctional protein derived from a single nucleotide sequence which may contain two or more genes or portions of genes with or without amino acid linker sequences. The genes should originally code for separate proteins, with at least two of them endowed with pharmacological action (e.g. action and targeting). “Notes from the fusion protein Working Group”, INN Working Document number 17.414 rev.

-ixibat	ileal bile acid transporter (IBAT) inhibitors, bile acid reabsorption inhibitors
barixibat (88), elobixibat (104), linerixibat (118), maralixibat chloride (113), odevixibat (119), volixibat (113)	
-leuton	5-lipo-oxygenase inhibitors, anti-inflammatory
atreleuton (78), diroleuton (118), epeleuton (118), fenleuton (72), setileuton (101), zileuton (63)	
<i>stat</i>	enzyme inhibitors
-becestat	beta secretase inhibitors
atabecestat (117), elenbecestat (117), umibecestat (119), lanabecestat (116), verubecestat (112)	
-glustat	ceramide glucosyltransferase inhibitors
duvoglustat (102), eliglustat (103), miglustat (85), sinbaglustat (121), venglustat (114)	
-stinel	N-methly-D-aspartate (NMDA) receptor co-agonists
apimostinel (115), gavestinel (77), licostinel (77), rapastinel (111), zelquistinel (121)	
-tinib	tyrosine kinase inhibitors
-ertinib	epidermal growth factor receptor (EGFR) inhibitors
abivertinib (119), befotertinib (123), canertinib (87), epertinib (115), lazertinib (117), mavelertinib (118), mobocertinib (121), olafertinib (121), osimertinib (113), rezivertinib (122), xiliertinib (121), zorifertinib (121)	
(b) category: ulixertinib (113), ravoxertinib (115) (Erk inhibitors)	
(c) category: afatinib (104), olmutinib (114), erlotinib (85), gefitinib (85), mubritinib (90), nazartinib (114), mubritinib (90), nazartinib (114)	

-tirom(-)

antihyperlidaemic; thyromimetic derivatives

acetiromate (30), axitirome (82), bentiromide (41), eprotirome (99), resmetirom (119), sobetirome (100)

-toclax

B-cell lymphoma 2 (Bcl-2) inhibitors, antineoplastics

obatoclax (94), navitoclax (103), venetoclax (111), imlatoclax (115), pelcitoclax (122), tapotoclax (121), mirzotamab clezutoclax (121), murizatoclax (122)

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24214

